GSK’s share price surged by 6% after it announced a multi-billion dollar deal to settle most of the remaining Zantac-related lawsuits against it.
Key Takeaways
-
GSK and other companies have faced lawsuits since the US FDA called for ranitidine products to be removed from the market in 2020.
The company has agreed to pay $2.2bn to settle around 80,000 outstanding US-based liability cases alleging that Zantac (ranitidine) caused...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?